Breaking Finance News

Summit Therapeutics (OTCMKTS:SMMT) target price raised to $30.00, reported today by Needham

Summit Therapeutics (OTCMKTS:SMMT) had its target price raised to $30.00 by Needham in a report released 10/5/2016. The new target price indicates a possible upside of 1.09% based on the company's last stock close price.

Previously on Friday September 16, 2016, H.C. Wainwright reported about Summit Therapeutics (OTCMKTS:SMMT) raised the target price from $0.00 to $26.00. At the time, this indicated a possible upside of 3.73%.

Yesterday Summit Therapeutics (OTCMKTS:SMMT) traded 65.90% higher at $14.35. The company’s 50-day moving average is $7.48 and its 200-day moving average is $7.68. The last stock close price is up 86.75% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 4,843,495 shares of Summit Therapeutics traded, up from an avg. volume of 94,922

Performance Chart

Summit Therapeutics (OTCMKTS:SMMT)

With a total market value of $0, Summit Therapeutics has with a one year low of $4.26 and a one year high of $19.75 .

A total of 4 analysts have released a report on Summit Therapeutics. zero analysts rating the company a strong buy, zero analysts rating the company a buy, zero analysts rating the company a hold, zero analysts rating the company a underperform, and finally zero analysts rating the company a sell with a 12-month price target of $22.00.

More About Summit Therapeutics (OTCMKTS:SMMT)

Summit Therapeutics plc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to treat genetic and infectious diseases in the United Kingdom and North America. The company is developing Ezutromid, an utrophin modulator product candidate that is in Phase II clinical trials used for to treat Duchenne muscular dystrophy disease; and Ridinilazole, an orally administered small molecule antibiotic, which is in Phase II clinical trials for the treatment of Clostridium difficile infection disease. It has strategic alliance with the University of Oxford to develop utrophin modulators. The company was formerly known as Summit Corporation plc and changed its name to Summit Therapeutics plc in February 2015. Summit Therapeutics plc was founded in 2003 and is based in Abingdon, the United Kingdom.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.